PD-1, PD-L1 and PD-L2 Expression in Well-Differentiated Small Bowel Gastrointestinal Neuroendocrine Tumours (Wd SB-NETs). Abstract #1680

Introduction: Treatment options for patients with advanced Wd SB-NETs are limited.
Aim(s): We describe immune cell infiltration in this disease group.
Materials and methods: Patients diagnosed with Wd (WHO grade 1-2) SB-NETs, who had provided informed consent for analysis of archival tissue, were eligible. Programmed death-ligand 1 (PD-L1), PD-L2, PD-1 and tumour infiltrating lymphocytes (TILs) were analysed by immunohistochemistry (IHC); PD-L1, PD1 and PD-L2 were also assessed with reverse transcription polymerase chain reaction (RT-PCR).
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Biomarkers
Presenting Author: Dr Angela Lamarca
Keywords: immunotherapy

To read results and conclusion, please login ...

Further abstracts you may be interested in

No result